95
Participants
Start Date
September 10, 2019
Primary Completion Date
December 31, 2023
Study Completion Date
November 30, 2026
Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1
Paclitaxel (albumin-bound) : 150 mg/m2, iv,d1. S-1 : 40\~60mg,bid, d1-14( BSA\<1.25m2,40mg;1.25m2≤BSA≤1.5m2,50mg;BSA\>1.5m2,60mg) Oxaliplatin: 85mg/m2, iv, d1. Twenty-one days per cycle, a total of four cycles, after two cycles of treatment, the tumor was evaluated. The clinical efficacy was evaluated as CR\\PR\\SD and decided by the investigator to continue the treatment for two cycles or directly.
RECRUITING
Beijing Cancer Hospital, Beijing
Peking University Cancer Hospital & Institute
OTHER